News

Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Hims & Hers CEO No Longer A Billionaire After Novo Nordisk Deal Collapses
The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...
Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Hims & Hers: Panic Sell Or Opportunistic Buy?
The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...
Zacks Investment Research on MSN21h
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...
SHAREHOLDER ALERT: Hims & Hers Health, Inc. Sued For Securities Fraud By Block & Leviton LLP August 25 Deadline To Seek To Serve As Lead Plaintiff
On behalf of an individual investor, Block & Leviton LLP filed a class action lawsuit today against Hims & Hers Health, Inc. (NYSE: HIMS), along with certain individuals, alleging that they violated ...
Asianet Newsable on MSN1d
Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk Breakup
Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the ...